EGFR and non-small cell lung carcinoma: This NMA suggests that osimertinib and first-generation EGFR-TKIs combined with chemotherapy would be the optimal first-line treatment option for advanced NSCLC patients harboring EGFR 19 deletion mutation and 21 Leu858Arg mutation, respectively.